Get the Stockscreener App
2.945
0.51%
-0.025
Cabaletta Bio Inc stock is traded at $2.945, with a volume of 225.10K.
It is down -0.51% in the last 24 hours and down -5.89% over the past month.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
See More
Previous Close:
$2.97
Open:
$2.93
24h Volume:
225.10K
Relative Volume:
0.08
Market Cap:
$283.02M
Revenue:
-
Net Income/Loss:
$-158.52M
P/E Ratio:
-1.1657
EPS:
-2.5263
Net Cash Flow:
$-120.26M
1W Performance:
-7.37%
1M Performance:
-5.89%
6M Performance:
+34.93%
1Y Performance:
+66.01%
1-Day Range:
$2.86
$2.965
1-Week Range:
$2.84
$3.2799
52-Week Range:
$0.9857
$3.78
Cabaletta Bio Inc Stock (CABA) Company Profile
Name
Cabaletta Bio Inc
Sector
Industry
Phone
(267) 759-3100
Address
2929 ARCH STREET, PHILADELPHIA, PA
Compare CABA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
2.94 | 285.91M | 0 | -158.52M | -120.26M | -2.5263 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.64 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.21 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.13 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.94 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.26 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Resumed | Jefferies | Buy |
| Dec-20-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-10-24 | Initiated | UBS | Buy |
| Feb-05-24 | Initiated | Jefferies | Buy |
| Nov-29-23 | Initiated | William Blair | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | Stifel | Buy |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Jul-18-23 | Initiated | Guggenheim | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-30-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jun-30-21 | Initiated | Mizuho | Buy |
| Jan-08-21 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-20 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Initiated | Cowen | Outperform |
| Nov-19-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Morgan Stanley | Overweight |
View All
Cabaletta Bio Inc Stock (CABA) Latest News
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Heights Capital Management Inc. Sells 1,059,904 Shares of Cabaletta Bio, Inc. $CABA - MarketBeat
Merger Talk: Will Cabaletta Bio Inc announce a stock splitInflation Watch & Long-Term Safe Return Strategies - baoquankhu1.vn
Quarterly Earnings: Will Bowman Consulting Group Ltd benefit from seasonality2026 Top Gainers & Weekly Breakout Watchlists - baoquankhu1.vn
What are Cabaletta Bio Incs recent SEC filings showingWeekly Risk Report & Breakout Confirmation Trade Signals - baoquankhu1.vn
Cabaletta Bio Reports Promising Data from RESET Trials for Transformative Autoimmune Therapy - MSN
Cabaletta Bio (CABA) upgraded to buy: Here's what you should know - MSN
Cabaletta Bio Highlights Pivotal Myositis Trial, No-Preconditioning CAR-T Push at TD Cowen Conference - MarketBeat
Day Trade: What are Cabaletta Bio Inc.’s recent SEC filings showingJuly 2025 Sector Moves & Free Reliable Trade Execution Plans - baoquankhu1.vn
Aug Sectors: Is Cabaletta Bio Incs ROE strong enough2025 Analyst Calls & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Cabaletta Bio takes spotlight at Guggenheim Summit as autoimmune bet advances - MSN
Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Cabaletta Bio (CABA) to Release Quarterly Earnings on Thursday - MarketBeat
CABA SEC FilingsCabaletta Bio, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
TD Cowen Health Care Conference - marketscreener.com
Are healthcare stocks underperforming Biodesix (BDSX) so far this year? - Bitget
Are Medical Stocks Lagging Biodesix (BDSX) This Year? - Yahoo Finance
[Form 4] Cabaletta Bio, Inc. Insider Trading Activity - Stock Titan
Cabaletta Bio (CABA) grants 175,000 stock options to General Counsel - Stock Titan
Cabaletta Bio (CABA) CFO awarded 225,000-share stock option grant - Stock Titan
Gains Report: Can Cabaletta Bio Inc deliver consistent dividendsJuly 2025 Analyst Calls & Fast Gain Swing Alerts - baoquankhu1.vn
CABA Should I Buy - Intellectia AI
CABA Technical Analysis & ETF Price Forecast - Intellectia AI
Here’s why Jacob Funds established a position in Cabaletta Bio (CABA) - MSN
Millennium Management LLC's Strategic Acquisition of Cabaletta B - GuruFocus
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference - The Manila Times
Short Covering: Will Cabaletta Bio Inc announce a stock split2025 Price Targets & Scalable Portfolio Growth Methods - baoquankhu1.vn
Aug EndMonth: What drives SATLWs stock price2025 Market Sentiment & Stock Market Timing Techniques - baoquankhu1.vn
Dividend Watch: Is PECO stock a falling knife or bargain buyRisk Management & Growth Oriented Trade Recommendations - baoquankhu1.vn
CABA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Market Rankings: Is Cabaletta Bio Inc stock trending bullishJuly 2025 Analyst Calls & High Accuracy Swing Trade Signals - baoquankhu1.vn
Millennium Group (CABA) jointly reports 5.3% holding of 5.13M shares - Stock Titan
Aug Shorts: Does Cabaletta Bio Inc have strong EBITDA marginsJuly 2025 Update & Accurate Buy Signal Notifications - baoquankhu1.vn
Here’s Why Jacob Funds Established a Position in Cabaletta Bio (CABA) - Insider Monkey
Alyeska group reports 4.67% Cabaletta Bio (CABA) stake via 4.5M warrants - Stock Titan
What are Cabaletta Bio Inc.’s recent SEC filings showingPortfolio Update Summary & Daily Risk Controlled Trade Plans - mfd.ru
CABA News & Events - Intellectia AI
Best Swing Trade Stocks Right Now • Updated Daily - Benzinga
Pharma News: Why retail investors favor Cabaletta Bio Inc. stock2025 Historical Comparison & Fast Entry High Yield Tips - mfd.ru
Cabaletta Bio Kicks Off Pivotal Myositis Trial, Touts Automated CAR-T Manufacturing Path to 2027 BLA - MarketBeat
Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year? - Nasdaq
Aug Drivers: Is Cabaletta Bio Inc stock a smart retirement pickJuly 2025 Recap & Fast Moving Market Watchlists - baoquankhu1.vn
CABA News Today | Why did Cabaletta Bio stock go up today? - MarketBeat
Cabaletta Bio Takes Spotlight at Guggenheim Summit as Autoimmune Bet Advances - MyChesCo
Cabaletta Bio shares climb after insider purchases - MSN
Update Recap: Is Cabaletta Bio Inc stock overvalued or fairly priced2025 Macro Impact & AI Powered Market Entry Strategies - baoquankhu1.vn
Trend Review: Is Cabaletta Bio Inc stock overvalued or fairly pricedJuly 2025 Technicals & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Cabaletta Bio (CABA) and Ocular Therapeutix (OCUL) - The Globe and Mail
Cabaletta Bio to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - Quiver Quantitative
Cabaletta Bio Inc Stock (CABA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.01%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):